In the 50 years following the introduction of the first dry powder inhaler to the market, several
developments have occurred. Multiple-unit dose and multi-dose devices have been …

Dry powder inhalers have become increasingly attractive for pulmonary delivery of locally
and systemically effective medications. In comparison to the liquid counterparts, such as …

Dry powder inhalers (DPIs) are a widely accepted inhaled delivery dosage form, particularly
in Europe, where they currently are used by a large number of patients for the delivery of …

Many companies are now prioritizing the development of dry powder inhalers (DPIs) above
pressurized formulations of asthma drugs. A well-designed DPI and an appropriate powder …

A drug product combines pharmacologic activity with pharmaceutical properties. Desirable
performance characteristics are physical and chemical stability, ease of processing …

Pulmonary drug delivery is the focus of much research and development because of its
great potential to produce maximum therapeutic benefit. Among the available options the dry …

The pulmonary route is an interesting route for drug administration, both for effective local
therapy (asthma, chronic obstructive pulmonary disease or cystic fibrosis) and for the …

This review examines the key issues surrounding the development and preparation of
formulations for dry powder inhalers. The various inhaler devices that are currently available …

The search for alternatives to metered-dose inhalers has accelerated recently in a bid to find
effective products that do not use chlorofluorocarbon (CFC) propellants. This paper reviews …

Enhanced therapeutics are drug products derived from existing generic drugs that provide
additional benefits to the patients and the healthcare system. Enhanced therapeutics are …